• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Retinopathy-Pipeline Review H1 2017

    Diabetic Retinopathy-Pipeline Review H1 2017

    • Report Code ID: RW0001834331
    • Category Pharmaceuticals
    • No. of Pages 188
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Diabetic Retinopathy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

    Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters) , blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 5, 1, 34, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

    Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 5
    Diabetic Retinopathy - Overview 6
    Diabetic Retinopathy - Therapeutics Development 7
    Diabetic Retinopathy - Therapeutics Assessment 18
    Diabetic Retinopathy - Companies Involved in Therapeutics Development 28
    Diabetic Retinopathy - Drug Profiles 46
    Diabetic Retinopathy - Dormant Projects 165
    Diabetic Retinopathy - Discontinued Products 169
    Diabetic Retinopathy - Product Development Milestones 170
    Appendix 180

    List of Tables

    Number of Products under Development for Diabetic Retinopathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diabetic Retinopathy - Pipeline by Abzena Plc, H1 2017
    Diabetic Retinopathy - Pipeline by Acucela Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Aerpio Therapeutics Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Amakem NV, H1 2017
    Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
    Diabetic Retinopathy - Pipeline by Apollo Endosurgery Inc, H1 2017
    Diabetic Retinopathy - Pipeline by BCN Peptides SA, H1 2017
    Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2017
    Diabetic Retinopathy - Pipeline by Charlesson LLC, H1 2017
    Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
    Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H1 2017
    Diabetic Retinopathy - Pipeline by EyeGene Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
    Diabetic Retinopathy - Pipeline by Formycon AG, H1 2017
    Diabetic Retinopathy - Pipeline by Icon Bioscience Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Islet Sciences Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Kowa Company Ltd, H1 2017
    Diabetic Retinopathy - Pipeline by Lupin Ltd, H1 2017
    Diabetic Retinopathy - Pipeline by M's Science Corp, H1 2017
    Diabetic Retinopathy - Pipeline by Mabion SA, H1 2017
    Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2017
    Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H1 2017
    Diabetic Retinopathy - Pipeline by PanOptica Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Profarma, H1 2017
    Diabetic Retinopathy - Pipeline by Promedior Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Ribomic Inc, H1 2017
    Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H1 2017
    Diabetic Retinopathy - Pipeline by Targazyme Inc, H1 2017
    Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2017
    Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H1 2017
    Diabetic Retinopathy - Dormant Projects, H1 2017
    Diabetic Retinopathy - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Diabetic Retinopathy - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Diabetic Retinopathy - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Diabetic Retinopathy - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diabetic Retinopathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Abzena Plc
    Acucela Inc
    Aerie Pharmaceuticals Inc
    Aerpio Therapeutics Inc
    Amakem NV
    Antisense Therapeutics Ltd
    Apollo Endosurgery Inc
    BCN Peptides SA
    Biomar Microbial Technologies
    Charlesson LLC
    Coherus BioSciences Inc
    Crinetics Pharmaceuticals Inc
    Dimerix Bioscience Pty Ltd
    Dynamis Therapeutics Inc
    EyeGene Inc
    Foresee Pharmaceuticals LLC
    Fo
    rmycon AG
    Icon Bioscience Inc
    Islet Sciences Inc
    Kodiak Sciences Inc
    Kowa Company Ltd
    Lupin Ltd
    M's Science Corp
    Mabion SA
    Nemus Bioscience Inc
    Oculis ehf
    Ohr Pharmaceutical Inc
    PanOptica Inc
    Profarma
    Promedior Inc
    Regeneron Pharmaceuticals Inc
    Ribomic Inc
    Strongbridge Biopharma plc
    Targazyme Inc
    ThromboGenics NV
    VESSL Therapeutics Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//diabetic-retinopathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diabetic-retinopathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diabetic-retinopathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments